OPTN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OPTN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. OptiNose's Net Income for the three months ended in Dec. 2024 was $-0.36 Mil. OptiNose's Revenue for the three months ended in Dec. 2024 was $22.42 Mil. Therefore, OptiNose's net margin for the quarter that ended in Dec. 2024 was -1.61%.
The historical rank and industry rank for OptiNose's Net Margin % or its related term are showing as below:
The historical data trend for OptiNose's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiNose Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
-203.16 | -110.24 | -98.11 | -49.99 | -27.54 |
OptiNose Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-50.17 | -94.54 | -37.00 | 2.29 | -1.61 |
For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, OptiNose's Net Margin % distribution charts can be found below:
* The bar in red indicates where OptiNose's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
OptiNose's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -21.541 | / | 78.226 | |
= | -27.54 % |
OptiNose's Net Margin for the quarter that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -0.36 | / | 22.419 | |
= | -1.61 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiNose (NAS:OPTN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of OptiNose's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Marino Michael F Iii | officer: Chief Legal Officer & Corp Sec | C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Ramy A Mahmoud | officer: President & COO | 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
Paul Jr. Spence | officer: Chief Commercial Officer | 1507 POWNAL DRIVE, YARDLEY PA 19067 |
Anthony J Krick | officer: Chief Accounting Officer | 1020 STONY HILL ROAD, YARDLEY PA 19067 |
Peter K Miller | director, officer: Chief Executive Officer | C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087 |
Mvm Partners, Llc | 10 percent owner | OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
Michele Janis | officer: Acting Chief Financial Officer | 1020 STONY HILL ROAD, YARDLEY PA 19067 |
Victor M Clavelli | officer: Chief Commercial Officer | 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Kyle Dempsey | director | OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
Eric Bednarski | director | OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
Partners Llp Mvm | 10 percent owner | 30 ST. GEORGE STREET, LONDON X0 W1S SFH |
Keith A. Goldan | officer: Chief Financial Officer | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Joseph C Scodari | director | JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired • 03-20-2025
By Marketwired • 08-26-2024
By GuruFocus News • 11-11-2024
By Marketwired • 10-16-2024
By Marketwired • 08-02-2024
By GuruFocus News • 02-15-2025
By GuruFocus News • 11-21-2024
By Marketwired • 03-11-2025
By GuruFocus News • 02-13-2025
By GuruFocus News • 10-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.